

Mannogem[®] XL Mannitol USP/EP/JP

Simplify Patient Friendly Dose Formulation and Production

Background

Drug developers consistently face more complex demands for new forms and functionality of Oral Solid Dosage Forms (OSDF). These demands come from patients requiring forms that are highly functional and pleasing. There is also regulatory focus, such as recent Guidelines from the FDA¹, emphasizing the importance of considering the patient experience with the dose form. SPI Pharma is helping formulators face the challenge. Mannogem XL Mannitol is a breakthrough for the simplification of patient friendly dosage forms. XL allows formulators to meet the demand for unique functionality or appearance, increases development output, and reduces development time, while simplifying formulation and production.

Achieving the desired critical properties such as tensile strength, friability and disintegration time can be a multifaceted challenge for applications like chewable tablets, lozenges and ODTs. Formulators meet this challenge by using many different excipients in a single formulation, adding time and complexity to both the development process and, ultimately, the production process. Mannogem XL is an innovative, spray dried, compendial mannitol that offers significant advantages such as superior tabletability² and rapid disintegration to enable formulators to use a single excipient to meet complex formulation requirements.

Results

Excipients added to enhance tabletability can detract from the organoleptics of a formulation. Specifically, HPC can be gummy and MCC has a grittiness to it. Studies were undertaken to understand whether the use of Mannogem XL could enable the removal of HPC and MCC. Removal and/or reduction of these materials would therefore be highly beneficial, provided the tabletability and disintegration targets could be maintained.


We imitated a commercially available formula of a chewable tablet and studied the effect of incorporating Mannogem XL into the mix. Substituting XL for the spray dried mannitol competitor in this formulation produced tablets with a higher tensile strength and lower friability. As demonstrated in Table 1, the number of other binding excipients in the formulation could be reduced until only 4% MCC was left in the formulation. The resulting tablet weights and tablet thicknesses were reduced by approximately 10%. To confirm the benefit, the same reduction was taken using Competitor 1 spray dried mannitol.

Table 1- Standard formulation and formulations used in the simplified version

Formulation	Standard		Simplified	
Product	% of Blend	mg/ Tablet	% of Blend	mg/ Tablet
Spray Dried Mannitol	65%	811.7	73%	811.7
Actimask [®] 92M	14%	171.8	15%	171.8
HPC	4%	49.8	0%	0
PH102 (MCC)	10%	124.5	4%	47.8
Crospovidone	5%	62.3	6%	62.3
Mag. Stearate	2%	24.9	2%	24.9

Figure 1 shows Mannogem XL's enhanced tabletability is maintained

in the simplified formulation. Figure 2 shows superior tensile strength when using Mannogem XL when compared to competitive spray dried mannitol cannot maintain tablet robustness. Additionally, the tensile strength of the competitor's formulation only exceeds 1 MPa at high compression forces (30 kN). Such a formulation would not be acceptable for commercial manufacturing.









Figure 3 shows that the tablet robustness does not change in the simplified formulation while using Mannogem XL. In Figure 4, lower friability shows an increase in the tabletability of the formulation. Friability is unacceptably high for the formulation containing the competitor spray dried mannitol.



Conclusion

This data demonstrates the potential Mannogem XL Mannitol has to be used as an excipient that can greatly simplify the formulation approaches to rapidly develop a robust tablet formulation that has all of the requisite CQAs, namely high tablet robustness, rapid disintegration, and superior organoleptics.

This simplification potential has significant advantages as it enables more rapid development cycles, eliminating wider consideration of design space required when multiple excipients and levels of excipient are needed. Stability issues increase as the number of excipients in a formulation are increased. Mannogem XL Mannitol reduces the potential for stability issues.

References

- 1. Quality Attribute Considerations for Chewable Tablets. Guidance for Industry. CDER August 2018.
- 2. SPI Pharma Mannogem XL Superior Tabletability Technical Bulletin, January 2019.



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the costumer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND. WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILTY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.

Order# SPI-EXC-MGM-XL-0900-08201900 08-2019 | All rights reserved © 2019 SPI Pharma